Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris (ASSOCIATE)

This study has been completed.
Sponsor:
Information provided by:
Servier
ClinicalTrials.gov Identifier:
NCT00202566
First received: September 12, 2005
Last updated: June 15, 2011
Last verified: June 2011

September 12, 2005
June 15, 2011
June 2005
Not Provided
Improvement between baseline and end of treatment of the treadmill exercise tolerance test
Same as current
Complete list of historical versions of study NCT00202566 on ClinicalTrials.gov Archive Site
  • Rate pressure product
  • Clinical evaluation
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris
Evaluation of the Anti-anginal Efficacy and Safety of Oral Administration of Ivabradine Compared to Placebo on Top of Background Therapy With Atenolol in Patients With Stable Angina Pectoris. A Four-month Randomised Double-blind, Parallel Group International Multicentre Study.

To test whether ivabradine when given in combination with atenolol is able to improve the exercise tolerance of patients with stable angina pectoris

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Angina Pectoris
Drug: Ivabradine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
750
October 2007
Not Provided

Inclusion Criteria:

  • Chronic stable angina pectoris
  • Documented coronary artery disease
  • Previous treatment with atenolol or other beta-blocker agent
  • Exercise tolerance test positivity and stability

Exclusion Criteria:

  • Heart rate < 60 bpm
  • Congestive heart failure
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00202566
CL3-16257-057
Not Provided
Not Provided
Institut de Recherches Internationales Servier
Not Provided
Study Chair: Jean-Claude Tardif, Pr Montreal Heart Institute
Servier
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP